Vertex Pharma Live Stock Price Today, Share Analysis and Chart

Name: Vertex Pharmaceuticals, Inc.: Is Infosys Ltd. worth buying?
Item: Vertex Pharmaceuticals, Inc.
Rating: 1.900736125
Author: Trendlyne DVM scores

Await Turnaround

about

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, whe...

467.69 0.34 (0.07%)

29.02% Gain from 52W Low

232.5K

XNAS Volume

XNAS 23 Jan, 2026 11:26 AM (EST)

Low Financial Strength

27.8 / 100

Mid Valuation

39.8 / 100

Technically Neutral

56.7 / 100

Await Turnaround These stocks have poor financials and average valuation and momentum. Investors should be cautious about these stocks View Similar Embed DVM

506

1Yr Price target upside is 8%

25 analysts

Vertex Pharma Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Vertex Pharma Live Stock Price Today, Share Analysis and Chart

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, whe...

29.02% Gain from 52W Low

SWOT Analysis

Vertex Pharma Live Price Chart